About Altor Bioscience
Altor Bioscience is a company based in United States founded in 2002 by Hing Wong was acquired by NantHealth in June 2017.. Altor Bioscience has raised $92.71 million across 30 funding rounds from investors including NantHealth, HHS and National Cancer Institute. Altor Bioscience offers products and services including ANKTIVA, NK-92 Cell Line, and rBCG. Altor Bioscience operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter United States
- Founders Hing Wong
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Immunitybio, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$92.71 M (USD)
in 30 rounds
-
Latest Funding Round
$4.19 M (USD), Grant
Sep 30, 2018
-
Investors
NantHealth
& 3 more
-
Employee Count
Employee Count
-
Acquired by
NantHealth
(Jun 27, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Altor Bioscience
Altor Bioscience offers a comprehensive portfolio of products and services, including ANKTIVA, NK-92 Cell Line, and rBCG. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enhances immune system to treat bladder and other cancers.
Provides natural killer cells for bioanalytical testing in trials.
Recombinant BCG for addressing BCG shortages in cancer treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of Altor Bioscience
Altor Bioscience has successfully raised a total of $92.71M across 30 strategic funding rounds. The most recent funding activity was a Grant round of $4.19 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 30
- Last Round Grant — $4.2M
-
First Round
First Round
(26 Jul 2002)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2018 | Amount | Grant - Altor Bioscience | Valuation |
investors |
|
| Mar, 2017 | Amount | Series G - Altor Bioscience | Valuation |
investors |
|
| Jul, 2016 | Amount | Series F - Altor Bioscience | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Altor Bioscience
Altor Bioscience has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NantHealth, HHS and National Cancer Institute. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biomedical investment financing and active management services.
|
Founded Year | Domain | Location | |
|
Cancer research is conducted and supported by the institute.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Altor Bioscience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Altor Bioscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Altor Bioscience Comparisons
Competitors of Altor Bioscience
Altor Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Altor Bioscience
When was Altor Bioscience founded?
Altor Bioscience was founded in 2002.
Where is Altor Bioscience located?
Altor Bioscience is headquartered in United States.
Who is the current CEO of Altor Bioscience?
Hing Wong is the current CEO of Altor Bioscience. They have also founded this company.
Is Altor Bioscience a funded company?
Altor Bioscience is a funded company, having raised a total of $92.71M across 30 funding rounds to date. The company's 1st funding round was a Series F of $20M, raised on Jul 26, 2002.
What does Altor Bioscience do?
Altor Bioscience was founded in 2002 in the United States. Focus is placed on the biotechnology sector, where cell and immunotherapy products are developed for treating cancer and infectious diseases. The product pipeline features Anktiva, targeted at bladder and lung cancer. Operations center on advancing these therapeutic options through research and development efforts.
Who are the top competitors of Altor Bioscience?
Altor Bioscience's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
What products or services does Altor Bioscience offer?
Altor Bioscience offers ANKTIVA, NK-92 Cell Line, and rBCG.
Who are Altor Bioscience's investors?
Altor Bioscience has 4 investors. Key investors include NantHealth, HHS, National Cancer Institute, and Sanderling Ventures.